Development of an automatic rapid test system for blood diagnostics and immunoassays

AESKU. Group has received funding from the European Union's Fund for Region Growth 2014 – 2020 Program to develop an automated platform for the automation of Point-Of-Care (POC) Tests. Read more...

AESKU.AWARD 2022 goes to three outstanding researchers in autoimmunity

On June 10th, 2022, Aesku. Diagnostic’s “Aesku.Award for life contribution to autoimmunity” was awarded for the eighteenth time. Dr. Torsten Matthias, founder, and CEO of Aesku.Diagnostics, presented the awards to the prizewinners during the opening ceremony of the “13th International Congress on Autoimmunity”, which took place in Athens from June 10th to June 14th, 2022.

Dr. Matthias explained in his short introduction that the company considers the Aesku.Award an expression of its vision and philosophy, and he would like to share with this award the success of his company, from when others faced great problems, with those who achieved great things in the difficult time of the pandemic. Since its foundation 22 years ago, Aesku.Diagnostics supports explicitly interdisciplinary research in autoimmune diseases. He pointed out that it is one of the goals of the Aesku.Award is to stress the importance of research in autoimmune diseases and to show the progress in establishing autoimmunity as an independent field of study.

The prize was presented during the Opening Ceremony of the Congress. Read more...

Clinical Performance of AESKU.RAPID SARS-CoV-2 Antigen Test to detect Delta variant (B1.617.2)

Biomex has carried out a study to establish the performance of the AESKU.RAPID SARS-CoV-2 Antigen Test in detecting the SARS-CoV-2 Delta variant.

The testing was carried out with four infected and confirmed patients over a period of up to 9 days after onset of symptoms.A total of 26 nasal swabs were tested with the AESKU.RAPID SARS-CoV-2 Antigen Test and simultaneously analyzed through a PCR Test. The collection of the swabs was carried out in Germany with European subjects.

All samples up to Ct-values of 36.15 have been positive with the AESKU.RAPID SARS-CoV-2 Antigen Test. In some cases, even samples which have been negative in the PCR gave a slight positive result with the AESKU.RAPID SARS-CoV-2 Antigen Test. Thus, the requirement stipulated by the Paul-Ehrlich-Institut (PEI), that samples within the first 7 days after onset of symptoms should be detected positive, has been fulfilled.

In conclusion, the sensitivity of AESKU.RAPID SARS-CoV-2 Antigen Test to detect the delta variant is very high, as it detected all positive samples confirmed by the PCR.

Download the Complete Study (PDF Document)